Joshua Grube,1 Dariann Davis,2 Riley Regan,2 Isabella Ford,2 Joshua Wung,2 Janette Bow-Keola,1 Tyrone Sumibcay,1 Matthew Kao,1 Jonathan Phisayavong,3 Amir Meghdadi,4 Chris Berka,4 Enrique Carazzana,1 Kore Kai Liow1,2
1 John A. Burns School of Medicine, University of Hawaiʻi, Honolulu, HI
2 Alzheimer’s Neural Network EEG Research Laboratory, Hawaii Pacific Neuroscience, Honolulu, HI
3 JABSOM Biostatistics Core Facility, Department of Quantitative Health Sciences, University of Hawaiʻi
4 Advanced Brain Monitoring, Carlsbad, CA
Existing research has established an association between hypertension (HTN), mild cognitive impairment (MCI), and Alzheimer’s Disease (AD), and how uncontrolled HTN can increase the progression of MCI to AD. Brain Electrical Activity Mapping (BEAM) has been used to identify unique biomarkers useful for MCI diagnosis and other neurocognitive diseases. This project’s objective was to identify differences between BEAM biomarkers in patients with MCI only to those with a comorbid diagnosis of HTN. A retrospective chart review of patients with an MCI diagnosis who underwent BEAM testing was conducted at Hawaii Pacific Neuroscience. Additional criteria for inclusion were a history of HTN, no stroke or TBI within 2 years prior to BEAM testing, no concurrent antidepressant/antipsychotic medication use, and no diagnosis of other vascular diseases, such as Type II DM and various vasculitides. Initial analysis revealed no significant differences between MCI only (N=42) vs. MCI with HTN (N=11) groups for patients stratified by MMSE scores (25-30 for Group 1 [N=28] and 20-24 for Group 2 [N=18]) for Auditory Oddball (AO) N1 Peak Latency, AO P300 Maximum Amplitude, and AO P300 Maximum Latency. Further data collection will increase sample size/power, and other disease biomarkers may be explored.
